Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROphylactic Efanesoctocog Alfa Therapy Evaluated for Critical Joint Health in Hemophilia A Treatment: The PROTECT-ALT Study

NCT06684314 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06684314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06684314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROphylactic Efanesoctocog Alfa Therapy Evaluated for Critical Joint Health in Hemophilia A Treatment: The PROTECT-ALT Study
Lead sponsor
Sanofi
Phase
Observational
Overall status
Active, not recruiting
Start date
November 11, 2024
Completion date
August 28, 2031
Enrollment
79 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a